final -gsk vs ranbaxy-2012

8/3/2019 Final -Gsk vs Ranbaxy-2012

1/14

Company Profile Ranbaxy, India:

Ranbaxy Laboratories Limited (Ranbaxy), India's largest pharmaceuticalcompany, is an integrated, research based, international pharmaceuticalcompany, producing a wide range of quality, affordable generic medicines, trusted byhealthcare professionals and patients across geographies. Ranbaxy today has a presence in23 of the top 25 pharmaceutical markets of the world. The Company has a global footprintin 46 countries, world-class manufacturing facilities in 7 countries and serves customers iner 125 countries.

In June 2008, Ranbaxy entered into an alliance with one of the largest Japanese innovatorcompanies, Daiichi Sankyo Company Ltd., to create an innovator and genericpharmaceutical powerhouse. The combined entity now ranks among the top 20pharmaceutical companies, globally. The transformational deal will place Ranbaxy in ahigher growth trajectory and it will emerge stronger in terms of its global reach and in its

capabilities in drug development and manufacturing.

Company growing faster than the market.- example of Ranbaxyssuccess rate

Formation

Ranbaxy was started by Ranbir Singh and Gurbax Singh in 1937 as a distributor for aJapanese company Shionogi. The name Ranbaxy is a combination of the names of its firstowners Ranbir and Gurbax. Bhai Mohan Singh bought the company in 1952 from his cousinsRanbir and Gurbax. After Bhai Mohan Singh's son Parvinder Singh joined the company in1967, the company saw an increase in scale.

Product Portfolio: Ranbaxy

Using the finest R&D and Manufacturing facilities, Ranbaxy Laboratories Limitedmanufactures and markets generic pharmaceuticals, value added generic pharmaceuticals,branded generics, active Pharmaceuticals (API) and intermediates.The Company remainsfocused on ascending the value chain in the marketing of pharmaceutical substances and isdetermined to bring in increased revenues from dosage forms sales.

Ranbaxy's diverse product basket of over 5,000 SKUs available in over 125 countriesworldwide encompasses a wide therapeutic mix covering a majority of the chronic andacute segments. Healthcare trends project that the chronic treatment segments willoutpace the acute treatment segments, primarily driven by a growing aging population anddominance of lifestyle diseases. Our robust performance in Cardiovascular, Central NervousSystem, Respiratory, Dermatology, Orthopedics, Nutritionals and Urology segments, clearlyindicates that the Company has strengthened its presence in the fast-growing chronic andlifestyle disease segments.

1. Prescription Medicines:

Cephalexin (Sporidex), Ciprofloxacin (Cifran), Amoxycillin (Mox),Ofloxacin (Zanocin), Atorvastatin (Storvas), Ceftriaxone (Oframax),


2/14

1

Cefpodoxime (Cepodem), Co-amoxyclav (Moxclav), Cilanem(Imipenem+Cilastatin), Volini (Diclofenac combination), Silverex (SilverSulphadizine), Cepodem (Cefpodoxime), Verorab (Rabies vaccine)

2. Over the Counter Products:

volini spray,ointment,volitra gel, relaxyl gel, diprovate creat,haloxlotion,medsop,medsop acne etc


3/14

1

Company Profile: GlaxoSmithKline (GSK)

GlaxoSmithKline (GSK)is aBritish multinationalpharmaceutical, biologics,vaccinesand consumer healthcare companyheadquartered in London, United Kingdom. It is the world's third-largest pharmaceuticalcompany measured by revenues (afterJohnson & Johnson and Pfizer

GSK has a portfolio of products for major disease areas including asthma, cancer, viruscontrol, infections, mental health, diabetes and digestive conditions.[4] It also has a largeconsumer healthcare division which produces and markets oral healthcare and nutritionalproducts and over-the-counter medicinesincluding Sensodyne,Boost, Horlicks and Gaviscon.

GSK has a primary listing on the London Stock Exchangeand is a constituent of the FTSE100 Index. As of December 2011, it had a market capitalization of 73.8 billion, the fifth-largest of any company listed on the London Stock Exchange. It has a secondary listing onthe New York Stock Exchange

Product Portfolio: Gsks prescription medicines include treatments for a widerange of conditions such as infections, depression, skin conditions, asthma, heart and

circulatory disease and cancer. Products are in various stages of approval around the world

and may not be available in every country.

1. Prescription Medicines:

Advair, Altabax, Amerge, Argatroban , Arixtra, Arranon, Arzerra,

Avandamet, Avandaryl, Avandia, Avodart, BactrobanBeconase,

Benlysta, Bexxar,Ceftin, Coreg, Coreg CR, Dyazide, DynaCirc CR,

Entereg, Flonase, Flovent, HycamtinImitrex,Jalyn, Lamictal / Lamictal

ODT, Lamictal XR, Levitra, Lovaza, Malarone, Mepron, Promacta,

Relenza, Serevent, Staxyn, Tabloid, Timentin, Valtrex, Wellbutrin,

Wellbutrin SR, Zantac, Zofran, Zovirax, Zyban

2. Vaccines:

As infants and young children we visited the doctor to get our vaccinations andbooster shots. As adults, we hardly remember the sting from those shotsbut thosevaccines have worked to help us avoid some diseases altogether throughout ourlives.

Researchers are looking for easier ways to deliver vaccines. Instead of getting ashot, someday you may be able to:

Take a vaccine orally

Inhale a vaccine

Place a patch on your skin

Boostrix, Cervarix, Engerix-B , Fluarix, FluLaval, Havrix, Hiberix,Infanrix, Kinrix, Pediarix, Rotarix, Twinrix
http://en.wikipedia.org/wiki/Multinational_corporationhttp://en.wikipedia.org/wiki/Pharmaceutical_industryhttp://en.wikipedia.org/wiki/Biologichttp://en.wikipedia.org/wiki/Biologichttp://en.wikipedia.org/wiki/Vaccineshttp://en.wikipedia.org/wiki/Vaccineshttp://en.wikipedia.org/wiki/Johnson_%26_Johnsonhttp://en.wikipedia.org/wiki/Pfizerhttp://en.wikipedia.org/wiki/Asthmahttp://en.wikipedia.org/wiki/Mental_healthhttp://en.wikipedia.org/wiki/Diabeteshttp://en.wikipedia.org/wiki/Digestive_diseasehttp://en.wikipedia.org/wiki/GlaxoSmithKline#cite_note-about-3http://en.wikipedia.org/wiki/Sensodynehttp://en.wikipedia.org/wiki/Sensodynehttp://en.wikipedia.org/wiki/Boost_(health_food)http://en.wikipedia.org/wiki/Horlickshttp://en.wikipedia.org/wiki/Gavisconhttp://en.wikipedia.org/wiki/London_Stock_Exchangehttp://en.wikipedia.org/wiki/London_Stock_Exchangehttp://en.wikipedia.org/wiki/FTSE_100_Indexhttp://en.wikipedia.org/wiki/FTSE_100_Indexhttp://en.wikipedia.org/wiki/Market_capitalisationhttp://en.wikipedia.org/wiki/New_York_Stock_Exchangehttp://www.advair.com/http://www.altabax.com/http://us.gsk.com/products/assets/us_amerge.pdfhttp://www.argatroban.com/http://www.arixtra.com/http://www.arranon.com/http://us.gsk.com/products/assets/us_arzerra.pdfhttp://www.combinationtherapiessite.com/about-avandamet.htmlhttp://www.combinationtherapiessite.com/about-avandaryl.htmlhttp://www.avandia.com/http://www.avodart.com/http://gsk.com/products/prescription-medicines/bactroban.htmhttp://us.gsk.com/products/assets/us_beconase_aq.pdfhttp://www.benlysta.com/http://www.bexxar.com/http://us.gsk.com/products/assets/us_ceftin.pdfhttp://us.gsk.com/products/assets/us_coreg.pdfhttp://www.coregcr.com/http://us.gsk.com/products/assets/us_dyazide.pdfhttp://us.gsk.com/products/assets/us_dynacirc_cr.pdfhttp://www.entereg.com/http://www.flonase.com/http://www.gw-flovent.com/http://www.gsk.com/products/prescription-medicines/hycamtin.htmhttp://www.gsk.com/products/prescription-medicines/imitrex.htmhttp://www.jalyn.com/http://www.lamictal.com/http://www.lamictal.com/http://www.lamictalxr.com/http://www.levitra.com/http://www.lovaza.com/http://www.malarone.com/http://us.gsk.com/products/assets/us_mepron.pdfhttp://www.promactacares.com/http://www.relenza.com/http://us.gsk.com/products/assets/us_serevent_diskus.pdfhttp://www.staxyn.com/http://us.gsk.com/products/assets/us_tabloid.pdfhttp://www.gsk.com/products/prescription-medicines/timentin.htmhttp://www.valtrex.com/http://us.gsk.com/products/assets/us_wellbutrin_tablets.pdfhttp://us.gsk.com/products/assets/us_wellbutrinSR.pdfhttp://www.gsk.com/products/prescription-medicines/zantac.htmhttp://www.gsk.com/products/prescription-medicines/zofran.htmhttp://us.gsk.com/products/assets/us_zovirax.pdfhttp://us.gsk.com/products/assets/us_zyban.pdfhttp://www.boostrix.com/http://us.gsk.com/products/assets/us_cervarix.pdfhttps://www.gskvaccinesdirect.com/gsk/en/US/htdocs/products/ENGERIX/index.htmhttp://www.fluarix.com/http://us.gsk.com/products/assets/us_flulaval.pdfhttp://www.havrix.com/http://us.gsk.com/products/assets/us_hiberix.pdfhttps://www.gskvaccinesdirect.com/gsk/en/US/htdocs/products/INFANRIX/index.htmhttp://www.kinrix.com/hcp/http://www.pediarix.com/http://www.rotarix.com/http://www.twinrix.com/http://en.wikipedia.org/wiki/Pharmaceutical_industryhttp://en.wikipedia.org/wiki/Biologichttp://en.wikipedia.org/wiki/Vaccineshttp://en.wikipedia.org/wiki/Johnson_%26_Johnsonhttp://en.wikipedia.org/wiki/Pfizerhttp://en.wikipedia.org/wiki/Asthmahttp://en.wikipedia.org/wiki/Mental_healthhttp://en.wikipedia.org/wiki/Diabeteshttp://en.wikipedia.org/wiki/Digestive_diseasehttp://en.wikipedia.org/wiki/GlaxoSmithKline#cite_note-about-3http://en.wikipedia.org/wiki/Sensodynehttp://en.wikipedia.org/wiki/Boost_(health_food)http://en.wikipedia.org/wiki/Horlickshttp://en.wikipedia.org/wiki/Gavisconhttp://en.wikipedia.org/wiki/London_Stock_Exchangehttp://en.wikipedia.org/wiki/FTSE_100_Indexhttp://en.wikipedia.org/wiki/FTSE_100_Indexhttp://en.wikipedia.org/wiki/Market_capitalisationhttp://en.wikipedia.org/wiki/New_York_Stock_Exchangehttp://www.advair.com/http://www.altabax.com/http://us.gsk.com/products/assets/us_amerge.pdfhttp://www.argatroban.com/http://www.arixtra.com/http://www.arranon.com/http://us.gsk.com/products/assets/us_arzerra.pdfhttp://www.combinationtherapiessite.com/about-avandamet.htmlhttp://www.combinationtherapiessite.com/about-avandaryl.htmlhttp://www.avandia.com/http://www.avodart.com/http://gsk.com/products/prescription-medicines/bactroban.htmhttp://us.gsk.com/products/assets/us_beconase_aq.pdfhttp://www.benlysta.com/http://www.bexxar.com/http://us.gsk.com/products/assets/us_ceftin.pdfhttp://us.gsk.com/products/assets/us_coreg.pdfhttp://www.coregcr.com/http://us.gsk.com/products/assets/us_dyazide.pdfhttp://us.gsk.com/products/assets/us_dynacirc_cr.pdfhttp://www.entereg.com/http://www.flonase.com/http://www.gw-flovent.com/http://www.gsk.com/products/prescription-medicines/hycamtin.htmhttp://www.gsk.com/products/prescription-medicines/imitrex.htmhttp://www.jalyn.com/http://www.lamictal.com/http://www.lamictal.com/http://www.lamictalxr.com/http://www.levitra.com/http://www.lovaza.com/http://www.malarone.com/http://us.gsk.com/products/assets/us_mepron.pdfhttp://www.promactacares.com/http://www.relenza.com/http://us.gsk.com/products/assets/us_serevent_diskus.pdfhttp://www.staxyn.com/http://us.gsk.com/products/assets/us_tabloid.pdfhttp://www.gsk.com/products/prescription-medicines/timentin.htmhttp://www.valtrex.com/http://us.gsk.com/products/assets/us_wellbutrin_tablets.pdfhttp://us.gsk.com/products/assets/us_wellbutrinSR.pdfhttp://www.gsk.com/products/prescription-medicines/zantac.htmhttp://www.gsk.com/products/prescription-medicines/zofran.htmhttp://us.gsk.com/products/assets/us_zovirax.pdfhttp://us.gsk.com/products/assets/us_zyban.pdfhttp://www.boostrix.com/http://us.gsk.com/products/assets/us_cervarix.pdfhttps://www.gskvaccinesdirect.com/gsk/en/US/htdocs/products/ENGERIX/index.htmhttp://www.fluarix.com/http://us.gsk.com/products/assets/us_flulaval.pdfhttp://www.havrix.com/http://us.gsk.com/products/assets/us_hiberix.pdfhttps://www.gskvaccinesdirect.com/gsk/en/US/htdocs/products/INFANRIX/index.htmhttp://www.kinrix.com/hcp/http://www.pediarix.com/http://www.rotarix.com/http://www.twinrix.com/http://en.wikipedia.org/wiki/Multinational_corporation


4/14

1

3. Over the Counter Products:

Abreva, Alli , Aqua Fresh, Bc Powder, Beotene , Breath

Right , Chap-et ,Citrucel, Commit Legunge ,Debrox,

Ecotrin,Fiber Choice , Gly-oxide , Nicorette, Tagamet-HB , Targon, Tums.

GSK : the companies global

expansion

Early 1880s-Gsk formalized partnership in 1880 and Burroughs Wellcome &Company was established. Its prosperity owed much to Wellcome's marketing flair,involving bold advertising, using medical and scientific conferences, and the creation in1884 of the Tabloid trademark.

The business expanded and spread to many countries, but the partnership was ended afterjust 15 years with the death of Burroughs

Early 1890sThe original company that John K Smith founded went through numerousmergers and acquisitions.Probably the most important and far-reaching was the company'sabsorption in 1891 of French, Richards and Company, another respected drugwholesaler.

This combination gave the new company an inventory of hundreds of varied products,including fine perfumes, liniments, tonics, hair oil, cough medicine, and acomprehensive range of home remedies. It marked the company's first venture intoconsumer brands.

In the mid 1950s food products represented over 30 % or more of turnover only

in argentian and Australia.

Growth for Smith, Kline and French in the early 1900s came mainly because of a discoverybyJoseph England that led to Eskay's Neurophosphates, used chiefly in thetreatment of nervous disorders.

From 1893 everything made at Smith, Kline and French was assayed for standards ofquality and purity.

By 1957 GSK represented in nearly 70 countries and had nine overseassubsidiary headquarters with manufacturing facilities at Verona , wadeville ( south Africa).Neuro carried the Smith, Kline and French name beyond the boundaries of theUS into Latin America at a time when trade there was in its infancy. The Neuro

remained on the company list until 1971.

1.Karachi-( Pakistan)

2.Bombay-(India)

3.Melbourne-(Australia)

4.Palmerston north-(New Zealand)


5/14

1

5.Niterori( Brazil)

VACCINE is a reason for GSK overseas expansion :

The expansion of GSK was mainly possible because of the effort they had taken toR&D the effective VACCINES .

Vaccines for the prevention of hepatitis A, hepatitis B, invasive disease caused by H,influenzae, chickenpox, diphtheria, pertussis, tetanus and others.

boostrix , cervarix , fluarix , priorix ,twinrix and etc are some of the brands thatemerged under the GSK

The biggest break it had got was in the 1980s when it had this ZANTAC productlaunched world wide resulting in 34 % of the companies profit share.

Gsk followed international strategyStandardized foreign production for exports was the main objective.

The entry strategy into global market for GSK was through

licensing

contract manufacturing enthusiastic internationalizers because each moleculecost millions , they incur huge R&d expenses

ethnocentric orientation : home country is superior, sees similarities In foreigncountries.

Gsk and Ranbaxy differed in entry strategy

As GSK started expanding early after the 2nd world war it had a complete different scenarioit was more of providing the best healthcare medication at affordable price keeping in mindthe environmental condition which proved to be a important factor in the companies longterm growth aspect. It came into reckoning and had by then created value of its own andfrom then there was no stepping backward .

The company started its global expansion in the field of consumer goods later with itsadvanced R&D technology and formulation of moleculesit had developed a market in the pharmaceutical sector

Ownership strategy :

GSK followed the more traditional approach of

MERGERS and ACQUISITIONS.

Conducted a sophisticated approach to pricing for

1. Developed world


6/14

1

2. Middle income countries

3. Least developed countries

Challenges faced by GSK in global expansion:

Growth:

Broadening and balancing the portfolio, and movingaway from a reliance on'white pills/western markets'.GSK are diversifying business to create a more balanced product portfolio and move awayfrom a reliance on traditional white pill, western markets. Sales generated from thesemarkets and products have decreased from 40% in 2007, to 25% in 2010. Over time thisshould help to reduce the adverse impact of patent expirations on the Group.GSK expect togenerate future sales growth by strengthening our core pharmaceuticals business andsupplementing it with increased investment in growth areas such as emerging markets,

vaccines, Japan, dermatology and Consumer Healthcare.Sales in Emerging Markets

were up 22%, vaccines up 15%, Japan up 14%, dermatology up 6% (on a pro-forma basisexcluding 2010 acquisitions) and Consumer Healthcare up 5% for 2010.

Plans executed :

1.Drive growth in the pharmaceutical business in the core markets

2.Fulfil the potential of Emerging Markets

3.Expand the business in Japan

4.Build our leadership in dermatology

5.Grow the Vaccines and Consumer Healthcare business

Deliver more

products of value Transforming R&D to ensure GSKnot only deliver the current pipeline butare also able to sustain the flow of products for years to come .With the aim of sustaining anindustry-leading pipeline of products that deliver value for healthcare providers, we havebeen focusing on improving rates of return and delivering the best science in our R&Dorganization. This has required a multi-faceted approach.

For example GSKhave increased the level of externalization of research, taken difficult

decisions around pipeline progressions and focused on disease areas where GSKbelievethe prospects for successful registration and launch of differentiated medicines are greater.

We have one of the largest development pipelines in the industry with approximately 30late-stage assets. The vast majority of these programmes address unmet medical need andimportantly nearly two-thirds are new chemical entities or new vaccines.

Plans executed :

1.Focus on the best science

top 10 pharmaceutical companiesworldwide, IMS MIDAS MAT

JUNE -2011


7/14

1

2.Diversify through externalization

3.Re-personalise R&D

4.focus on return on investment

Simplifying :

Simplifying GSK operating model to ensure that it is fit for purpose and able to support ourbusiness in the most cost efficient way.

As business continues to change shape, it is essential that GSK transform the operatingmodel to reduce complexities, improve efficiencies and reduce cost. Through our globalrestructuring programme, we have removed 1.7 billion of cost since 2008 and are on trackto deliver our target of 2.2 billion of annual savings by 2012.These savings have beenextracted from developed country sales and marketing, support functions, R&D andmanufacturing infrastructure and reinvested in higher returning activities such as emergingmarkets, vaccines and consumer healthcare.

plan executed :

1.Evolve the commercial model

2.Re-shape manufacturing

3.Streamline the processes.

4.Reduce working capital

Gsk is now a renowned brand in the field of pharmaceutical sector:

GSK AND RANBAXY position in Indian market :

It is now into the top 10 pharmaceuticalcompany in the world in terms of trade,having a 14 % share of the totalpharmaceutical industry .

GSK has contributed immenselytowards the vaccines segment productcategory

in 4th .Ranbaxy in d 3rd place

GSK


8/14

1

Gsk has a wide range of coverage with 150 countriesoperating under it.

44 countries Europe

3 countries North America

14 countries Central and SouthAmerica

3 countries Caribbean

13 countries Asia and Austrasia

8 countries south Asia

6 countries Africa

4 countries Middle east

Reason for success:

1.It has contributed the pharma industry with-Biopharmaceuticals, Steriles, Cephalosporins andPenicillins, Solid Dose, Liquids, Creams, and Ointments.

2.Supply to over 150 countries worldwide

3.Facilities approved by US, EU, Japan, and International regulatory agencies

4.Technical expertise and resources

5.Development and new product introduction in conjunction with GSK R&D resource

6.Highly developed and proven methods for technology transfer

7.Commitment to quality, safety, and sustainability

8.Specializing in complex, difficult to produce products

9.Cost-effective supply solutions

10.Expertise in Lean manufacturing processes

11.Corporate global support network

12.Large company strength and small company flexibility

13.Scalable process capability

14.Proven record in contract manufacturing and packaging

15.Commitment to quality-Quality is a mindset that underpins the whole ethos of how we work. It meansdoing what is right, first time, every time. GSKis at the forefront of process optimization with the application ofmethodologies that include Process Analytical Technology (PAT) and Quality by Design (QbD). A testament to this isour excellent quality, regulatory, compliance, and environmental facilities record.

16.State-of-the-art manufacturing-GSKhas dedicated, state-of-the-art facilities for the manufactureof products from actives through bulk and finished product supply. GSK can offer co-located R&D API Pilot Plants,

where we can provide early phase clinical requirements as well as commercial scale-up.

17.Security of supply-GSKis committed to security of supply. The combination of GSK in-housemanufacturing capabilities and world-class logistics operations means GSKhave a sound track record in ensuringpatients and customers have the products they need, on time and in full.

18.Competitive prices- the most important to have survived in this intense fieldof business :GSK have a culture of continuous improvement coupled with operationalexcellence and lean sigma. We are committed to removing waste and complexity from ouroperations so that we can deliver competitively priced products of the highest quality.


9/14

1

Ranbaxy India first overseas venture:

In 1998, Ranbaxy entered the United States, the world's largestpharmaceuticals market and now the biggest market for Ranbaxy,accounting for 28% of Ranbaxy's sales in 2005.

For the twelve months ending on 31 December 2005, the company's global sales were at US$1,178 million with overseas markets accounting for 75% of global sales (USA: 28%, Europe:17%, Brazil, Russia, and China: 29%). For the twelve months ending on December 31, 2006,the company's global sales were at US $1,300 millions.

Most of Ranbaxy's products are manufactured by license from foreign pharmaceuticaldevelopers, though a significant percentage of their products are off-patent drugs that aremanufactured and distributed without licensing from the original manufacturer because thepatents on such drugs have expired.

Ranbaxy entry strategies:

Its geocentric orientation

Ownership strategies:

Joint venture was the kind of strategy followed by Ranbaxy .

Ranbaxy worldwide:

Global Pharma Companies are experiencing an ever changing landscape ripe withchallenges and opportunities. In this challenging environment Ranbaxy is enhancing itsreach leveraging its competitive advantages to become a top global player.

Driven by innovation andspeed to market we focus ondelivering world-classgenerics at an affordableprice. Our unwaveringdetermination to achieveexcellence leads us to newglobal benchmarks. Ourpeople have consistentlyrisen above all challengesmaximized opportunities andpositioned Ranbaxy as aleader in the global genericsspace.

Ranbaxys global footprintextends to 46 countriesembracing different localesand cultures to form a familyof 50 nationalities with anintellectual pool of some ofthe best minds in the world.


10/14

1

Ranbaxy stepping success in pharmaceutical sector:

RANBAXY in 1977 had joint ventured with LAGAS (Nigeria)

In 1990 ranbaxy was 1st given a breakthrough in US market for doxyciline and gets apatent right.

Ranbaxy enters into agreement with US company Eli lilly & co to venture into INDIANMARKET

1993- Ranbaxy reaches china a market that was open.

Global alliance with GSK for drug discovery and development.

2000-Ranbaxy us crosses US $100million , fastest growing company in US

2003- the economic times award for corporate excellence for the company of theyear -2002 -2003

2006-

acquires be tabs pharmaceuticals

acquires unbranded generic business of GSK in Italy and spain

acquiers terapla, largest independent generic pharma company in

Romania for us $ 324 Mn

invalidates pfizers 995 lipitor U.S.patent

2008- Ranbaxy reaches settlement on world top selling drugs Lipitor with Pfizer andastra Zeneca

2010- Ranbaxy delivers quarterly sales of US $ 500 Mn for the first time.

2011- celebrate golden jublie IN 1998 RANBAXY had a defining moment when it wascredited by US to launch its own products under its name in the worlds biggestpharmaceutical sector.

The failure :

The US Food and Drug Administration (FDA) has banned the import of more than 30 drugsmade by Ranbaxy, India's largest drugmaker. The ban - which includes generic copies ofsimvastatin (Zocor) and the antiviral drug acyclovir - covers the drugs made at two Ranbaxyplants which the FDA says failed to meet current Good Manufacturing Practice (cGMP)standards.


11/14

1

The FDA investigated the two plants, in Dewas and Paonta Sahib, India, early in 2008.Investigators found 'significant cGMP deviations', which include inadequate cross-contamination control, inadequate sterile processing operations, and a lack of recordkeeping. No safety issues have been found with the drugs themselves - and the regulatorrecommends patients continue to take any Ranbaxy medications they have beenprescribed.

Ranbaxy had been known more for its advancement and achievements but thennothing is taken for granted because all are under JOINT VENTURE . it is in termsDICTATED under some CONDITIONS

Companies end up with the orgin :

The sale of promoter's stake by the Singh family in Ranbaxy has taken the industry by'surprise'.Ranbaxy promoter, the Singh family, sold their 34 per cent stake in the companyto Japanese company Daiichi Sankyo on Wednesday for Rs 9,576 crore (Rs95.76 billion).

Conclusion:

Based on the analysis there are various challenges in global expansion .

It is not easy to venture into new markets as a brand with its hostcountry tributes.

The opportunity should be tapped and worked upon to increase marketshare.

To identify the potential market

Competition in PHARMACEUTICAL SECTOR is very HIGH

Different strategies should be adopted for different countries

The external and internal environmental factor plays vitalrole in entering the potential market.

Recommendations to a DOMESTIC COMPANY :

We have taken an example ofMICRO-LABS one of the leading

GENERIC pharmaceutical company in INDIA.

MICRO-LABS being a INDIAN company by origin should follow the

policies which RANBAXY followed and follows , they should create ahealthy and effective environment within the country and then try toVENTURE into the GIANT GLOBAL PHARMA MARKETS.

JOINT VENTURE would be the need of the MOMENT because the world hasnot yet fully recovered with the RECESSION which covered the advancedcountries like a sheet of snow .


12/14

1

MICRO-LABS can follow the MULTI DOMESTIC STRATEGY where in it caninitially get into the COMPETITIVE MARKET and then create A MARKET OFITS OWN.

INTERNATIONAL STRATEGY can be a failure because it requires hugeCAPITAL INVESTMENT ADVERTISING will be EXPENSIVE.

MICRO-LABS for INITIAL advancement can TARGET the C & D group ofCOUNTRIES for EXPORTS .

By 2015 global position of MICROLABS

Micro Labs will be on the threshold ofachieving the prestigious status of a BigGeneric Company in the globalpharmaceutical space.

Microlabs will be building critical mass inexisting markets and developing business innew markets like USA, East Europe, NorthAfrica and South America. The group haspresence in over 30 countries with groundlevel operations in 15 countries, exporting allmajor dosages on every therapeutic segment.

The target growth expected

Export of all major dosages in every therapeutic segment

Corporate offices in 10 countries including UK, Thailand, Russia, Vietnam &Ukraine

Manufacturing sites approved by USA FDA, UK MHRA, Indonesia DOH, TGAAustralia, MEDSAFE New Zealand, HEALTH Canada and MCC South Africa

Independent marketing and operations with experienced sales teams

Focus on ethical promotion (brand building) sale of branded Genericdrugs

Strategic marketing alliances with local transnational marketingcompanies.


13/14

1

TRARGET products -Therapeutic Range

Analgesics / Anti-pyretics

Anti-allergics(Antihistamines)

Anti-anginals

Anti-arrhythmics

Anti-asthmatics /Bronchodilators

Anti-Bacterials

Anti-depressants

Anti-diarrhoeals

Anti-epileptics

Anti-Fungals (Topical andSystemic)

Anti-helminthics Anti-hypertensives

Anti-Hyperurecemil

Anti-inflammatories(NSAIDs)

Anti-malerials

Anti-obesity Drugs

Anti-parkinsons

Anti-psychotics

Anti-thrombotics / Anti-Platelets

Anti-Virals Anxiolytics

Cerebral Activators

Cough and Coldpreparations

Dental Specialities

Dermatologicals

Disease modifying Anti-rheumatic drugs (DMARD)

Diuretics

Haematinics

Hormones / Hormone analogues

Hypnotics

Lipid Lowering Agents

Liver tonic / Hepatoprotectors

Nephrologicals

Nutraceuticals / Anti-oxidants

Ophthalmologicals

Oral Hypoglycemic Agents (Diabetologicals)

Osmotic Derivatives
http://www.microlabsltd.com/dproducts/listproduct#Analgesics%20/%20Anti-pyreticshttp://www.microlabsltd.com/dproducts/listproduct#Anti-allergics%20(Antihistamines)http://www.microlabsltd.com/dproducts/listproduct#Anti-allergics%20(Antihistamines)http://www.microlabsltd.com/dproducts/listproduct#Anti-anginalshttp://www.microlabsltd.com/dproducts/listproduct#Anti-arrhythmicshttp://www.microlabsltd.com/dproducts/listproduct#Anti-asthmatics%20/%20Bronchodilatorshttp://www.microlabsltd.com/dproducts/listproduct#Anti-asthmatics%20/%20Bronchodilatorshttp://www.microlabsltd.com/dproducts/listproduct#Anti-Bacterialshttp://www.microlabsltd.com/dproducts/listproduct#Anti-depressantshttp://www.microlabsltd.com/dproducts/listproduct#Anti-diarrhoealshttp://www.microlabsltd.com/dproducts/listproduct#Anti-epilepticshttp://www.microlabsltd.com/dproducts/listproduct#Anti-Fungals%20(Topical%20and%20Systemic)http://www.microlabsltd.com/dproducts/listproduct#Anti-Fungals%20(Topical%20and%20Systemic)http://www.microlabsltd.com/dproducts/listproduct#Anti-helminthicshttp://www.microlabsltd.com/dproducts/listproduct#Anti-hypertensiveshttp://www.microlabsltd.com/dproducts/listproduct#Anti-Hyperurecemilhttp://www.microlabsltd.com/dproducts/listproduct#Anti-Hyperurecemilhttp://www.microlabsltd.com/dproducts/listproduct#Anti-inflammatories%20(NSAIDs)http://www.microlabsltd.com/dproducts/listproduct#Anti-inflammatories%20(NSAIDs)http://www.microlabsltd.com/dproducts/listproduct#Anti-malerialshttp://www.microlabsltd.com/dproducts/listproduct#Anti-obesity%20Drugshttp://www.microlabsltd.com/dproducts/listproduct#Anti-parkinsonshttp://www.microlabsltd.com/dproducts/listproduct#Anti-psychoticshttp://www.microlabsltd.com/dproducts/listproduct#Anti-thrombotics%20/%20Anti-Plateletshttp://www.microlabsltd.com/dproducts/listproduct#Anti-thrombotics%20/%20Anti-Plateletshttp://www.microlabsltd.com/dproducts/listproduct#Anti-Viralshttp://www.microlabsltd.com/dproducts/listproduct#Anxiolyticshttp://www.microlabsltd.com/dproducts/listproduct#Cerebral%20Activatorshttp://www.microlabsltd.com/dproducts/listproduct#Cough%20and%20Cold%20preparationshttp://www.microlabsltd.com/dproducts/listproduct#Cough%20and%20Cold%20preparationshttp://www.microlabsltd.com/dproducts/listproduct#Dental%20Specialitieshttp://www.microlabsltd.com/dproducts/listproduct#Dermatologicalshttp://www.microlabsltd.com/dproducts/listproduct#Disease%20modifying%20Anti-rheumatic%20drugs%20(DMARD)http://www.microlabsltd.com/dproducts/listproduct#Diureticshttp://www.microlabsltd.com/dproducts/listproduct#Haematinicshttp://www.microlabsltd.com/dproducts/listproduct#Hormones%20/%20Hormone%20analogueshttp://www.microlabsltd.com/dproducts/listproduct#Hypnoticshttp://www.microlabsltd.com/dproducts/listproduct#Lipid%20Lowering%20Agentshttp://www.microlabsltd.com/dproducts/listproduct#Liver%20tonic%20/%20Hepatoprotectorshttp://www.microlabsltd.com/dproducts/listproduct#Nephrologicalshttp://www.microlabsltd.com/dproducts/listproduct#Nutraceuticals%20/%20Anti-oxidantshttp://www.microlabsltd.com/dproducts/listproduct#Ophthalmologicalshttp://www.microlabsltd.com/dproducts/listproduct#Oral%20Hypoglycemic%20Agents%20(Diabetologicals)http://www.microlabsltd.com/dproducts/listproduct#Osmotic%20Derivativeshttp://www.microlabsltd.com/dproducts/listproduct#Analgesics%20/%20Anti-pyreticshttp://www.microlabsltd.com/dproducts/listproduct#Anti-allergics%20(Antihistamines)http://www.microlabsltd.com/dproducts/listproduct#Anti-allergics%20(Antihistamines)http://www.microlabsltd.com/dproducts/listproduct#Anti-allergics%20(Antihistamines)http://www.microlabsltd.com/dproducts/listproduct#Anti-anginalshttp://www.microlabsltd.com/dproducts/listproduct#Anti-arrhythmicshttp://www.microlabsltd.com/dproducts/listproduct#Anti-asthmatics%20/%20Bronchodilatorshttp://www.microlabsltd.com/dproducts/listproduct#Anti-asthmatics%20/%20Bronchodilatorshttp://www.microlabsltd.com/dproducts/listproduct#Anti-Bacterialshttp://www.microlabsltd.com/dproducts/listproduct#Anti-depressantshttp://www.microlabsltd.com/dproducts/listproduct#Anti-diarrhoealshttp://www.microlabsltd.com/dproducts/listproduct#Anti-epilepticshttp://www.microlabsltd.com/dproducts/listproduct#Anti-Fungals%20(Topical%20and%20Systemic)http://www.microlabsltd.com/dproducts/listproduct#Anti-Fungals%20(Topical%20and%20Systemic)http://www.microlabsltd.com/dproducts/listproduct#Anti-helminthicshttp://www.microlabsltd.com/dproducts/listproduct#Anti-hypertensiveshttp://www.microlabsltd.com/dproducts/listproduct#Anti-Hyperurecemilhttp://www.microlabsltd.com/dproducts/listproduct#Anti-inflammatories%20(NSAIDs)http://www.microlabsltd.com/dproducts/listproduct#Anti-inflammatories%20(NSAIDs)http://www.microlabsltd.com/dproducts/listproduct#Anti-malerialshttp://www.microlabsltd.com/dproducts/listproduct#Anti-obesity%20Drugshttp://www.microlabsltd.com/dproducts/listproduct#Anti-parkinsonshttp://www.microlabsltd.com/dproducts/listproduct#Anti-psychoticshttp://www.microlabsltd.com/dproducts/listproduct#Anti-thrombotics%20/%20Anti-Plateletshttp://www.microlabsltd.com/dproducts/listproduct#Anti-thrombotics%20/%20Anti-Plateletshttp://www.microlabsltd.com/dproducts/listproduct#Anti-Viralshttp://www.microlabsltd.com/dproducts/listproduct#Anxiolyticshttp://www.microlabsltd.com/dproducts/listproduct#Cerebral%20Activatorshttp://www.microlabsltd.com/dproducts/listproduct#Cough%20and%20Cold%20preparationshttp://www.microlabsltd.com/dproducts/listproduct#Cough%20and%20Cold%20preparationshttp://www.microlabsltd.com/dproducts/listproduct#Dental%20Specialitieshttp://www.microlabsltd.com/dproducts/listproduct#Dermatologicalshttp://www.microlabsltd.com/dproducts/listproduct#Disease%20modifying%20Anti-rheumatic%20drugs%20(DMARD)http://www.microlabsltd.com/dproducts/listproduct#Diureticshttp://www.microlabsltd.com/dproducts/listproduct#Haematinicshttp://www.microlabsltd.com/dproducts/listproduct#Hormones%20/%20Hormone%20analogueshttp://www.microlabsltd.com/dproducts/listproduct#Hypnoticshttp://www.microlabsltd.com/dproducts/listproduct#Lipid%20Lowering%20Agentshttp://www.microlabsltd.com/dproducts/listproduct#Liver%20tonic%20/%20Hepatoprotectorshttp://www.microlabsltd.com/dproducts/listproduct#Nephrologicalshttp://www.microlabsltd.com/dproducts/listproduct#Nutraceuticals%20/%20Anti-oxidantshttp://www.microlabsltd.com/dproducts/listproduct#Ophthalmologicalshttp://www.microlabsltd.com/dproducts/listproduct#Oral%20Hypoglycemic%20Agents%20(Diabetologicals)http://www.microlabsltd.com/dproducts/listproduct#Osmotic%20Derivatives


14/14

1

Symptomatic slow acting drug against OA (SYSADOA)

source:

1. http://www.ranbaxy.com/

2.http://www.gsk.com/

3.ims health information and consulting services india pvt. Ltd

4.http://www.glassdoor.com/Interview/GlaxoSmithKline-Interview-

Questions-E3477.htm

5. http://economictimes.indiatimes.com/ranbaxy-laboratories-ltd/infocompanylisting/companyid-13218.cms
http://www.microlabsltd.com/dproducts/listproduct#Symptomatic%20slow%20acting%20drug%20against%20OA%20(SYSADOA)http://www.ranbaxy.com/http://www.gsk.com/http://www.glassdoor.com/Interview/GlaxoSmithKline-Interview-Questions-E3477.htmhttp://www.glassdoor.com/Interview/GlaxoSmithKline-Interview-Questions-E3477.htmhttp://www.microlabsltd.com/dproducts/listproduct#Symptomatic%20slow%20acting%20drug%20against%20OA%20(SYSADOA)http://www.ranbaxy.com/http://www.gsk.com/http://www.glassdoor.com/Interview/GlaxoSmithKline-Interview-Questions-E3477.htmhttp://www.glassdoor.com/Interview/GlaxoSmithKline-Interview-Questions-E3477.htm

final -gsk vs ranbaxy-2012

Documents